January 2, 2018
PolyAurum has leased lab and office space in the Pennovation Center, a 58,000 square foot business incubator and laboratory located in the Grays Ferry Section of Philadelphia, that aligns and integrates researchers, innovators, and entrepreneurs for the commercialization of research discoveries. According to Deb Travers, CEO of PolyAurum, the choice was easy. The Pennovation Center is just south of the University of Pennsylvania campus where some of the development work will continue. The two campuses are a short walk or shuttle ride from each other. The Center has a modern industrial vibe that appeals to startups. There is ample conferencing and collaboration space which is important as you meet with investors. And don’t underestimate the beauty of free parking which none of the other incubators within the city limits provides. Finally, the Penn Center for Innovation Ventures group is right on campus. Said Travers, “We still get a lot of support from PCI Ventures as a young startup. Now I can just walk down the hall to ask questions.”
January 15, 2018
PolyAurum is pleased to announce that it has hired Dr. Neha Saxena, PhD as its new Director of Product Development. Neha comes to PolyAurum from Amend Surgical, where she worked on novel bone fillers. “She has the experience in nanoparticle development and characterization that we need at this critical juncture as we move full time development out of the laboratory of Dr. David Cormode, Assistant Professor in Radiology at the Perelman School of Medicine at the University of Pennsylvania into our own laboratory at the Pennovation Center in the Grays Ferry area of Philadelphia”, said Deb Travers, PolyAurum’s CEO.
Neha has a B.S. in Biomedical Engineering,from the University of Texas at Austin. Shew earned her MS and PHD in Materials Science and Engineering from the University of Florida, Gainesville.
November 13, 2017
PolyAurum announced today that Dr. Thais Sielecki, PhD will join the company as Vice President and Chief Scientific Officer. Dr. Sieleck comes to PolyAurum after a distinguished career working for companies such as Cytokine, Bristol-Myers Squibb and Dupont Merck. She has a successful track record and expertise in the areas of preclinical and early clinical science while maintaining an innovative and creative approach toward leadership. She has extensive experience in managing projects in drug delivery, oncology, inflammation, anti-infectives, and women’s health with multiple IND submittals as well as managing the scientific/business development/legal/regulatory teams with leadership in decision making on product portfolio balance, therapeutic area focus, and overall research/development strategy.
Dr. Sielecki earned her BS in Organic Chemistry and Psychology from the University of Maryland, her PhD in Organic Chemistry from Colorado State University and did post-doctoral studies in organic chemistry at Stanford University. “Thais is the perfect person to head up our early development efforts and to help us stay focussed on filing an IND to start clinical studies. We are thrilled to have her on board”, said Deb Travers, PolyAurum’s President and CEO.
October 20, 2017
PolyAurum announced today that it has successfully secured an exclusive worldwide license to the intellectual property described in PCT/US2015/021198 – “Polyphosphazene delivery systems for metal nanocrystals for biomedical applications” from the University of Pennsylvania and the Penn State Research Foundation. This comprehensive patent application covers composition of matter for a wide range of nanocrystals and polymers, as well as all foreseen medical (human and veterinary) uses for the nanoparticles. The patent is under active review by the US Patent Office.
PolyAurum is a preclinical stage biotechnology startup spun out of the University of Pennsylvania. The company is developing biodegradable gold nanoparticles to amplify the effect of radiation therapy in patients with locally advanced non-resectable tumors. Used in conjunction with radiation therapy, the gold nanoparticles accumulate selectively in tumors and significantly increase the destruction of tumor cells compared to radiation therapy alone. Because the nanoparticles are too large to enter normal tissue, there is no increase in damage to healthy tissues adjacent to the tumor.
August 2, 2017
PolyAurum presented its biodegradable nanoparticle technology to a packed room of investors at the Keiretsu Forum Northwest Capital Expo in Seattle, Washington on August 2, 2017. The audience was comprised of investors from various Keiretsu chapters along the West Coast, independent investors and representatives from numerous Family Offices in the country. The company was introduced by Bernard Rudnick of Capgenic Advisors and an active Keiretsu member and the investment committee for the Keiretsu Capital Fund.
Deb Travers, President and CEO of PolyAurum, said “Getting all these active investors into a room to hear your story is incredible. We had so much interest in the technology, people were lined up to talk to me.” The company will now go through a due diligence process with the Keiretsu organization, with investments following successful completion.
Keiretsu is the largest angel group in the world with more than 50 chapters worldwide. In 2016, they made $almost 72M in investments, 22% of which were in the life sciences.
July 28, 2017
PolyAurum is being featured in a July 30 article in the business section of the Philadelphia Inquirer. The article speaks to CEO, Deb Travers motivation and plans for the company and to the incredible biodegradable gold nanoparticle technology which has the potential to significantly enhance radiation therapy for cancer patients. The author of the article – Diane Mastrull – saw Travers present at the Angel Venture Fair at the Union League in Philadelphia and liked the story of the company and its founders and leader. Mastrull frequently features local entrepreneurs in her articles.
Cancer survivor becomes a cancer fighter at a Philly start-up
July 27, 2017
The NIH’s National Institute of Biomedical Imaging and Bioengineering has awarded PolyAurum a $225,000 grant to support development of its biodegradable gold nanoparticles. This is added to a $200,000 grant received from the University City Science Center – a Philadelphia based startup accelerator in December of last year. These awards validate the science and serve as a springboard for our development program and attracting matching funding from early stage venture capital and angel groups.